Cite
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
MLA
Gonzales, Emmanuel, et al. “Efficacy and Safety of Maralixibat Treatment in Patients with Alagille Syndrome and Cholestatic Pruritus (ICONIC): A Randomised Phase 2 Study.” Lancet, vol. 398, no. 10311, Oct. 2021, pp. 1581–92. EBSCOhost, https://doi.org/10.1016/S0140-6736(21)01256-3.
APA
Gonzales, E., Hardikar, W., Stormon, M., Baker, A., Hierro, L., Gliwicz, D., Lacaille, F., Lachaux, A., Sturm, E., Setchell, K. D. R., Kennedy, C., Dorenbaum, A., Steinmetz, J., Desai, N. K., Wardle, A. J., Garner, W., Vig, P., Jaecklin, T., Sokal, E. M., & Jacquemin, E. (2021). Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet, 398(10311), 1581–1592. https://doi.org/10.1016/S0140-6736(21)01256-3
Chicago
Gonzales, Emmanuel, Winita Hardikar, Michael Stormon, Alastair Baker, Loreto Hierro, Dorota Gliwicz, Florence Lacaille, et al. 2021. “Efficacy and Safety of Maralixibat Treatment in Patients with Alagille Syndrome and Cholestatic Pruritus (ICONIC): A Randomised Phase 2 Study.” Lancet 398 (10311): 1581–92. doi:10.1016/S0140-6736(21)01256-3.